Workflow
西安国际医学投资股份有限公司关于回购股份注销完成暨股份变动的公告

Core Viewpoint - The company has completed the repurchase and cancellation of shares, reducing its total share capital and enhancing shareholder value through improved earnings per share [2][8][12]. Group 1: Share Repurchase Details - The company repurchased a total of 19,304,400 shares, which accounts for 0.8540% of the total share capital prior to the cancellation [2][6]. - Following the cancellation, the total share capital decreased from 2,260,382,715 shares to 2,241,078,315 shares [2][9]. - The repurchase was conducted using self-owned funds and a special loan for stock repurchase, with a total expenditure between RMB 100 million and RMB 150 million, and a maximum repurchase price of RMB 9.16 per share [3][4]. Group 2: Implementation and Compliance - The repurchase was executed from May 27, 2024, to May 9, 2025, with a total transaction amount of RMB 100,019,214.1, excluding transaction fees [6]. - The company adhered to the regulations set forth by the Shenzhen Stock Exchange regarding share repurchase disclosures, providing monthly updates on the progress [5]. Group 3: Impact of Share Cancellation - The cancellation of shares is expected to enhance earnings per share and improve returns for shareholders without significantly affecting the company's financial, operational, or debt servicing capabilities [8]. - The shareholding structure remains compliant with listing requirements, and there will be no change in control of the company as a result of this transaction [8][13]. Group 4: Future Arrangements - The company will proceed with necessary legal and regulatory filings following the completion of the share cancellation [10].